By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Drugs and Therapies have been presented. According to news originating from Tokushima, Japan, by NewsRx correspondents, research stated, "Tumour necrosis factor-alpha (TNF-alpha) is a pleiotropic cytokine that plays an essential role in inflammation and apoptosis. Our previous study suggested that TNF-alpha-induced activation of matrix metalloproteinase-9 (MMP-9) resulted in the destruction of acinar tissue in the salivary glands of patients with Sjogren's syndrome (SS) via disruption of the acinar cell-basement membrane."
Our news journalists obtained a quote from the research from the University of Tokushima, "Recently, a wide array of biological agents has been designed to inhibit TNF, including etanercept and adalimumab. In this study, we demonstrate the suppressive effect of anti-TNF agents on TNF-alpha-induced MMP-9 production in NS-AV-AC, an immortalized human salivary gland acinar cell line. NS-AV-AC cells were treated with etanercept or adalimumab after TNF-alpha treatment. MMP-9 production and enzymatic activity were, respectively, visualized by real-time PCR and ELISA assay, and evaluated by gelatin zymography, and apoptosis was evaluated by DNA fragmentation assay. TNF-alpha induced the production of MMP-9 in NS-SV-AC cells. However, this production was greatly inhibited by treatment with etanercept or adalimumab. In addition, TNF-alpha-induced DNA fragmentation was prevented by treatment with etanercept or adalimumab."
According to the news editors, the research concluded: "These results may indicate that anti-TNF agents would have therapeutic efficacy for preventing destruction of the acinar structure in the salivary glands of patients with SS."
For more information on this research see: Targeting TNF-alpha suppresses the production of MMP-9 in human salivary gland cells. Archives of Oral Biology, 2013;58(12):1761-1768. Archives of Oral Biology can be contacted at: Pergamon-Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. (Elsevier - www.elsevier.com; Archives of Oral Biology - www.elsevier.com/wps/product/cws_home/203)
The news correspondents report that additional information may be obtained from K. Aota, University of Tokushima, Grad Fac Dental, Inst Hlth Biosci, Dept. of Oral Med, Tokushima 7708504, Japan (see also Drugs and Therapies).
Keywords for this news article include: Asia, Antirheumatics, Pharmaceuticals, Japan, Tokushima, Treatment, Adalimumab, Etanercept, Therapeutics, Immunologic Agents, Drugs and Therapies, Monoclonal Antibodies, Tumor Necrosis Factor (TNF) Inhibitors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC